 This is a placebo-controlled, double-blind, multicenter, randomized study for preliminary evaluation of the efficacy and safety of combining bevacizumab with cisplatin or carboplatin and etoposide in patients with previously untreated extensive-stage small cell lung cancer SCLC. 